Literature DB >> 33083351

Long-Term GeneXpert Positivity after Treatment for Pulmonary Tuberculosis.

Luisa Costantini1, Marco Marando2, Pietro Gianella2.   

Abstract

Tuberculosis (TB) is a cause of ill health and death worldwide. Since 2010, the diagnostic process has strongly relied on GeneXpert assays on biological specimens. Xpert MTB/RIF is an automated nucleic acid amplification test (NAAT) for Mycobacterium tuberculosis and rifampicin resistance, endorsed by the World Health Organization and the US Food and Drug Administration. Xpert is used in many countries as the initial diagnostic test for tuberculosis. Nevertheless, the reliability of GeneXpert positive tests in patients with a history of TB is largely unknown, due to possible false-positive results (i.e., GeneXpert-positive but culture-negative patients). We present a case report of a patient with a history of pulmonary TB, who was GeneXpert positive but culture negative on bronchoalveolar lavage 22 months after completion of appropriate antitubercular therapy. LEARNING POINTS: GeneXpert assays have a pivotal role in the diagnosis of tuberculosis (TB), with overall good sensitivity and excellent specificity.Patients with a history of TB can be GeneXpert positive up to several years after the end of appropriate antitubercular treatment.Further studies are warranted to fully understand the role of GeneXpert assays in the diagnostic algorithms of patients with a history of TB. © EFIM 2020.

Entities:  

Keywords:  GeneXpert; TB; Tuberculosis; false positives; retested patients

Year:  2020        PMID: 33083351      PMCID: PMC7546557          DOI: 10.12890/2020_001737

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  4 in total

1.  False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes.

Authors:  Grant Theron; Rouxjeane Venter; Liezel Smith; Aliasgar Esmail; Philippa Randall; Vishesh Sood; Suzette Oelfese; Greg Calligaro; Robin Warren; Keertan Dheda
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

2.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

3.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

4.  Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.

Authors:  Anne F Luetkemeyer; Cynthia Firnhaber; Michelle A Kendall; Xingye Wu; Gerald H Mazurek; Debra A Benator; Roberto Arduino; Michel Fernandez; Elizabeth Guy; Pamela Johnson; Beverly Metchock; Fred Sattler; Edward Telzak; Yun F Wang; Marc Weiner; Susan Swindells; Ian M Sanne; Diane V Havlir; Beatriz Grinsztejn; David Alland
Journal:  Clin Infect Dis       Date:  2016-02-02       Impact factor: 9.079

  4 in total
  4 in total

1.  Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa.

Authors:  Sian Floyd; Eveline Klinkenberg; Petra de Haas; Barry Kosloff; Thomas Gachie; Pete J Dodd; Maria Ruperez; Chali Wapamesa; Michael J Burnett; Nico Kalisvaart; Redwaan Vermaak; Tila Mainga; Albertus Schaap; Sarah Fidler; Linda Mureithi; Kwame Shanaube; Richard Hayes; Helen Ayles
Journal:  BMJ Open       Date:  2022-06-16       Impact factor: 3.006

2.  Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients.

Authors:  Raksha Rimal; Dhiraj Shrestha; Susil Pyakurel; Rashmi Poudel; Prasha Shrestha; Kul Raj Rai; Gokarna Raj Ghimire; Ganesh Rai; Shiba Kumar Rai
Journal:  BMC Infect Dis       Date:  2022-04-01       Impact factor: 3.090

3.  Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study.

Authors:  Inge Kroidl; Mohamed I M Ahmed; Sacha Horn; Christina Polyak; Allahna Esber; Ajay Parikh; Leigh Anne Eller; Hannah Kibuuka; Michael Semwogerere; Betty Mwesigwa; Prossy Naluyima; Joy Mary Kasumba; Jonah Maswai; John Owuoth; Valentine Sing'oei; Eric Rono; Rebecca Loose; Michael Hoelscher; Julie Ake; Christof Geldmacher
Journal:  EClinicalMedicine       Date:  2022-07-13

4.  TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis.

Authors:  Peter M Mbelele; Elingarami Sauli; Emmanuel A Mpolya; Sagal Y Mohamed; Kennedy K Addo; Sayoki G Mfinanga; Scott K Heysell; Stellah Mpagama
Journal:  Trop Med Int Health       Date:  2021-06-24       Impact factor: 3.918

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.